D. Arnold

Annals of Oncology · 2010–2022

A researcher in the Science corpus: 13 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from D. Arnold's perspective

Ordered by how strongly the researchers D. Arnold trusts endorse each paper. Same corpus, a different order for every researcher.

1. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. (Journal of Clinical Oncology)
2. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. (The Lancet Oncology)
3. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (Journal of Clinical Oncology)
4. The Consensus Molecular Subtypes of Colorectal Cancer (Nature Medicine)
5. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (Journal of Clinical Oncology)
6. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. (The Lancet Oncology)
7. Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival (Annals of Surgery)
8. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. (Journal of Clinical Oncology)
9. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated,… (Journal of Clinical Oncology)
10. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR (Nature)

Their papers

• Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2022) — 1,085 citations
• Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2019) — 1,834 citations
• Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017) — 774 citations
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) — 3,178 citations
• Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. (2015) — 637 citations
• Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) — 1,215 citations
• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) — 1,102 citations
• Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) — 930 citations
• Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) — 882 citations
• Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. (2013) — 1,130 citations
• Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. (2012) — 628 citations
• ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012) — 1,471 citations
• Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) — 917 citations